{"product_id":"mirumpharma-pestle-analysis","title":"Mirum PESTLE Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Mirum PESTLE analysis identifies external factors impacting the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003ePresents crucial factors in an organized format, streamlining complex topics for quick and informed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eMirum PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview displays the complete Mirum PESTLE analysis document. The structure, content, and formatting are exactly what you'll receive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003ePESTLE Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUncover the external forces impacting Mirum with our PESTLE Analysis. We explore political, economic, social, technological, legal, and environmental factors. Gain crucial insights into the company's operating landscape and future challenges. Make informed decisions with our detailed assessment of Mirum's external environment. Access actionable intelligence immediately. Buy the full PESTLE Analysis now for expert-level insights!\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment policies favoring biopharmaceutical innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment policies are crucial; funding from NIH and PDUFA boost biopharma R\u0026amp;D, benefiting Mirum. The Bipartisan Budget Act of 2018 provided significant NIH funds for drug research. The FDA's PDUFA VII (2023-2027) aims to enhance drug review efficiency. In 2024, NIH's budget is approximately $47.1 billion, supporting innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approval processes affecting therapy timelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMirum faces significant political hurdles due to regulatory approval processes. The FDA's rigorous review can substantially delay therapy launches. The average drug approval time is around 10-12 years. Expedited pathways, like Breakthrough Therapy, offer potential time savings. In 2024, the FDA approved 55 novel drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of healthcare legislation on market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealthcare legislation significantly shapes market access for companies like Mirum. The Affordable Care Act (ACA) in the U.S. has expanded patient access, potentially boosting demand for treatments. Drug pricing reforms, a focus in 2024-2025, could affect Mirum's pricing and market strategies. For example, the Inflation Reduction Act aims to lower drug costs, which could influence Mirum's revenue projections. In 2024, the pharmaceutical market is valued at $1.48 trillion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan drug designations and incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernments offer incentives for orphan drug development, like market exclusivity and tax credits. These incentives are crucial for companies like Mirum, focusing on rare liver diseases. The FDA has granted orphan drug designation to over 7,000 drugs. This can significantly boost a drug's profitability and market lifespan. These incentives can lower development costs and expedite regulatory approvals. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eOrphan Drug Act of 1983 spurred development.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e7+ years of market exclusivity post-approval.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eTax credits for clinical trial expenses.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eReduced regulatory fees.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical events and regulatory risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitical events and varying political climates globally pose regulatory and economic risks for international businesses like Mirum. These factors directly influence Mirum's ability to launch and market its products across different regions, potentially disrupting supply chains and market access. For instance, political instability in key markets can lead to sudden policy changes or trade restrictions. Regulatory hurdles, such as stringent approval processes, can significantly delay product commercialization. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePolitical instability in regions like Eastern Europe has caused a 20% decrease in foreign direct investment in the last year.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eNew regulations in the EU have increased pharmaceutical approval times by an average of 18 months.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eTrade wars have led to a 15% increase in import tariffs in some sectors.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical Winds: Navigating Mirum's Landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical factors heavily influence Mirum. Government funding like NIH's ~$47.1B in 2024 boosts R\u0026amp;D. Healthcare laws, such as the ACA, impact market access and pricing. Orphan drug incentives provide crucial support. Geopolitical events create market risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData (2024-2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding \u0026amp; Regulations\u003c\/td\u003e\n\u003ctd\u003eDrug development, approval times.\u003c\/td\u003e\n\u003ctd\u003eFDA approved 55 novel drugs in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Legislation\u003c\/td\u003e\n\u003ctd\u003eMarket access, pricing strategies.\u003c\/td\u003e\n\u003ctd\u003ePharma market valued $1.48T in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeopolitical Instability\u003c\/td\u003e\n\u003ctd\u003eSupply chains, market access\u003c\/td\u003e\n\u003ctd\u003e20% FDI decrease in unstable regions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic downturns impacting funding and investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEconomic downturns can significantly impact funding and investment in biopharma. Global economic fluctuations influence capital availability for research and commercialization. In 2024, venture capital funding in biotech saw a decrease, affecting companies like Mirum. For instance, Q1 2024 biotech funding dropped by 20% compared to Q4 2023. This can constrain Mirum's growth plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and reimbursement pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePricing and reimbursement pressures are intensifying from governments and private payers, aiming to curb drug costs and price hikes, which directly affects Mirum's profitability. For instance, the US government's Inflation Reduction Act of 2022 allows Medicare to negotiate drug prices, potentially impacting Mirum. In 2024, the pharmaceutical industry faced an average price increase of only 0.8%, reflecting these pressures. This environment necessitates innovative pricing strategies and demonstrating significant clinical value for market access. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and interest rate fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation and interest rate fluctuations significantly impact Mirum. Rising inflation increases operational costs, such as raw materials and labor. For example, in early 2024, inflation in the US hovered around 3-4%, affecting various sectors. \u003c\/p\u003e\n\u003cp\u003eChanges in interest rates influence borrowing costs for Mirum, affecting investment decisions and profitability. If interest rates rise, Mirum's cost of capital increases. The Federal Reserve's moves in 2024, with potential rate adjustments, are vital. \u003c\/p\u003e\n\u003cp\u003eThese economic shifts affect consumer spending and market demand for Mirum's products or services. High interest rates can curb consumer spending. The economic environment in 2024\/2025 is marked by volatility. \u003c\/p\u003e\n\u003cp\u003eMirum needs to adapt to these conditions through strategic pricing, cost management, and financial planning. Monitoring inflation rates and interest rate decisions is crucial for business success. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket size and growth in rare disease treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe market for rare disease treatments is a significant economic factor for Mirum. Projections show robust growth, offering opportunities for companies specializing in this field. The global rare disease therapeutics market was valued at $190.3 billion in 2023. It is expected to reach $428.9 billion by 2032. This represents a CAGR of 9.5% from 2024 to 2032.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eMarket size in 2023: $190.3 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eProjected market size by 2032: $428.9 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCAGR (2024-2032): 9.5%.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMirum faces currency exchange rate risks due to its global operations. Fluctuations can affect reported revenue and profitability, especially in volatile markets. For instance, a strong USD negatively impacts earnings from regions with weaker currencies. In 2024, currency volatility increased, impacting many multinational firms. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eThe Eurozone saw fluctuations against the USD, impacting companies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEmerging markets' currencies, like the Brazilian Real, faced volatility.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCompanies hedge currency risks using financial instruments.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic Headwinds Facing Mirum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic instability impacts Mirum via funding and market demand. Venture capital in biotech decreased in Q1 2024. Interest rate hikes by the Federal Reserve could increase borrowing costs for Mirum.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eEconomic Factor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding\u003c\/td\u003e\n\u003ctd\u003eReduced investments\u003c\/td\u003e\n\u003ctd\u003e20% biotech funding decrease in Q1 2024 vs. Q4 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflation\u003c\/td\u003e\n\u003ctd\u003eIncreased costs\u003c\/td\u003e\n\u003ctd\u003eUS inflation ~3-4% in early 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest Rates\u003c\/td\u003e\n\u003ctd\u003eHigher borrowing costs\u003c\/td\u003e\n\u003ctd\u003eFederal Reserve rate adjustments in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eociological factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy and awareness for rare diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient advocacy groups significantly impact rare disease research and treatment access. Increased public awareness of conditions like those Mirum addresses can shift research priorities. For instance, in 2024, advocacy efforts helped secure $1.5B in funding for rare disease research. Mirum's patient-centric approach aligns with this trend, supporting drug development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare access and disparities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealthcare access and disparities significantly influence Mirum's market penetration. In 2024, the US saw over 27 million uninsured individuals, potentially limiting access to Mirum's therapies. Disparities in care, impacting specific patient populations, can hinder treatment reach. Focusing on diverse patient needs is essential for effective therapy impact. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician and patient acceptance of new therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhysician and patient acceptance of new therapies hinges on trust and awareness. A 2024 study showed 60% of patients trust new medicines. Awareness of options is also crucial; only 45% of patients are well-informed. This impacts adoption rates, affecting market penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of rare diseases on patients and families\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRare and progressive liver diseases significantly affect patients and families. These diseases create substantial emotional, physical, and financial burdens. The need for effective therapies highlights the importance of companies like Mirum. This unmet need fuels the demand for innovative treatments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eApproximately 300 million people worldwide live with a rare disease.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eOver 7,000 rare diseases have been identified, with many affecting the liver.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe average annual cost of care for a rare disease patient can exceed $20,000.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTalent attraction and retention in specialized fields\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMirum's success hinges on its ability to attract and retain top talent in rare disease drug development. This is particularly crucial given the specialized nature of the field. In 2024, the turnover rate in the pharmaceutical industry was approximately 11.6%, highlighting the competitive landscape for skilled professionals. The demand for experienced professionals in this sector is high, with an estimated 15% projected growth in related job roles by 2025. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eHigh demand for specialized skills.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCompetitive job market with high turnover rates.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eProjected job growth in the sector by 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSocietal Shifts Shaping Healthcare's Future\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSociological factors significantly influence Mirum's operations. Patient advocacy groups, like the EveryLife Foundation, play a vital role. Healthcare access, influenced by economic conditions and healthcare policies, affects treatment reach. Physician and patient trust in new therapies impacts market acceptance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\u003c\/td\u003e\n\u003ctd\u003ePrioritizes research.\u003c\/td\u003e\n\u003ctd\u003e$1.5B in 2024 for rare diseases.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess\u003c\/td\u003e\n\u003ctd\u003eLimits therapy reach.\u003c\/td\u003e\n\u003ctd\u003e27M+ uninsured in US in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrust\u003c\/td\u003e\n\u003ctd\u003eAffects adoption rates.\u003c\/td\u003e\n\u003ctd\u003e60% patient trust in new meds (2024).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56070763577728,"sku":"mirumpharma-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/mirumpharma-pestle-analysis.png?v=1749431830","url":"https:\/\/swotanalysistemplates.com\/products\/mirumpharma-pestle-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}